Independent Research
OGN Analysis
7 pieces of research on Organon & Co.. We find the signal management buried in the earnings call.
Organon & Co. Stock Jumps on Takeover Rumors at Just 3.7x Earnings
Organon & Co. stock surged on unconfirmed reports of takeover interest, drawing attention to a women's health company with $6.2bn in trailing revenue priced at …
Read analysis →Organon & Co. Draws Takeover Interest at a 3.6x Earnings Valuation
Organon & Co. shares are jumping on reports the women's health company is attracting buyout interest, with no formal bid confirmed and a 3.6x forward P/E that m…
Read analysis →Organon Gets 24% Sun Pharma Buyout Bid at $13.25 Floor Price
Sun Pharma's all-cash offer for Organon at a 24% premium converts the stock from a fundamentals story into a merger arbitrage trade.
Read analysis →Sun Pharma Buys Organon & Co. for $11.75 Billion in All-Cash Deal
Sun Pharma agreed to acquire Organon & Co. for approximately $11.75 billion in an all-cash deal at a 24% premium, sending OGN shares to a 52-week high.
Read analysis →Sun Pharma's $13 Billion Bid Sends Organon & Co. Surging 31%
Organon shares surged 31% on reports of a $13 billion takeover bid from Sun Pharma, though the deal remains unconfirmed and speculative.
Read analysis →Sun Pharma Reportedly Near $12 Billion Deal for Organon, Stock Jumps 25%
Sun Pharmaceutical is reportedly nearing a $12 billion cash acquisition of Organon & Co., sending shares up 25%, though the stock's muted reaction at $8.83 sign…
Read analysis →